| Stockholders’ Equity |
Note
2 – Stockholders’ Equity
Common
Stock
During
the three months ended March 31, 2025, we issued the following shares of common stock.
| |
● |
On
January 17, 2025, we issued 3,688 shares of common stock to a former employee, net of 1,781 shares of common stock withheld for income
and FICA taxes owed upon the distribution of the shares. |
| |
|
|
| |
● |
On
January 27, 2025, we sold 1,030,972
shares of our common stock, pre-funded warrants to purchase up to 7,019,700
shares of our common stock (the “Pre-Funded Warrants”), and accompanying Series A warrants to purchase up to 8,050,672
shares of our common stock (the “Series A Warrants”) and Series B warrants to purchase up to 4,025,336
shares of our common stock (the “Series B Warrants” and collectively with the Series A Warrants, the “Common
Warrants”) for net proceeds of $4.4
million, after deducting placement agent fees and offering-related expenses under a best efforts public offering (the
“Offering”)at a combined purchase price
of $0.615
for institutional investors and $0.7975
for the Company’s Chief Executive Officer and certain board members. The Common Warrants both have an exercise price of $0.65
per share of common stock, and will be exercisable beginning on the effective date of stockholder approval of the issuance of the
shares upon exercise of the warrants (“Warrant Stockholder Approval”). The Series A Warrants will expire on the
five-year anniversary date of stockholder approval and the Series B Warrants will expire on the eighteen-month anniversary date of
stockholder approval. At March 31, 2025, Pre-Funded Warrants for the purchase of 6,494,000
remained outstanding and unexercised, but were fully exercised as of April 14, 2025.
|
| |
|
|
| |
● |
On
January 31, 2025, we issued 6,252 shares of common stock to Berg Capital Markets, LLC in connection with a consulting agreement. |
During the three months ended
March 31, 2024, we issued the following shares of common stock.
| |
● |
On January 22, 2024, we issued 6,203 shares of common stock to five of our executive officers and one employee, net of 2,373 shares of common stock withheld for income taxes owed upon the distribution of the shares. |
| |
|
|
| |
● |
On January 25, 2024, we issued 5,000 shares of common stock to Elion Oncology, Inc. (“Elion”) in satisfaction of the third milestone event under a license agreement. |
| |
|
|
| |
● |
On January 30, 2024, we closed a public offering for the sale of 476,000 shares of common stock, pre-funded warrants to purchase up to 1,079,555 shares of common stock in lieu of shares of common stock, and common warrants to purchase up to 1,555,555 shares of our common stock. The common warrants have an exercise price of $4.50, are immediately exercisable and expire on January 30, 2029. The shares of common stock were offered at a combined public offering price of $4.50 per share and accompanying common warrant and $4.4999 per pre-funded warrant and accompanying common warrant. The pre-funded warrants had an exercise price of $0.0001 and were exercised in full simultaneously with the closing of the public offering in exchange for 1,079,555 shares of our common stock. We received $6.3 million in net proceeds from the public offering, after deducting the fees of the placement agent and other offering-related expenses.
|
| |
|
|
| |
● |
On February 5, 2024, we issued 1,250 shares of common stock to a consultant in accordance with their consulting agreement. |
| |
|
|
| |
● |
On March 5, 2024, we issued 3,223 shares of common stock to a former employee, net of 1,377 shares of common stock withheld for income and FICA taxes owed upon the distribution of the shares. |
|